DEPLOY

Buying guide

Apple Watch vs Stelo in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Key differences

On DEPLOY's record, Stelo has more verified real-world deployments (2 versus 1) than Apple Watch as of 2026; DEPLOY counts a deployment only when confirmed at a named site with a primary source.

  • Apple Watch has more capabilities independently verified as autonomous (3 vs 0).
  • Stelo has the lower recorded price.
  • Stelo has more verified real-world deployments (2 vs 1).
Attribute
ManufacturerAppleDexcom
Form factorbiometricbiometric
Maturitycommercialcommercial
Autonomy3 verified autonomous
Availabilityshipping-nowshippingshipping-nowshipping
Price$399-$799 (actual sale price)$89-$99 (actual sale price)
Capability claims
  • Detects irregular heart rhythm (autonomous, verified)
  • Tracks heart health (autonomous, verified)
  • Tracks blood oxygen (SpO2) (claimed-only, claimed)
  • Tracks fitness and activity (autonomous, verified)
  • Tracks sleep (claimed-only, claimed)
Brain
Verified deployments1Apple2Dexcom, Dexcom
Privacy practices13cloud-upload, third-party-sharing, location-tracking, on-device-processing, training-data-use, data-sale, data-retention, biometric-storage, data-deletion-control, data-sale, data-deletion-control, data-retention, biometric-storage4biometric-storage, training-data-use, third-party-sharing, data-deletion-control
Sources on file2712

Track this matchup

Get told the moment Apple Watch or Stelo changes. Verified changes only, the second they are real. No press-release noise.

Apple Watch

Verified changes only. No press-release noise.

Stelo

Verified changes only. No press-release noise.

Editorial summaries

Apple Watch

The Apple Watch (current Series 11 and Ultra 3, September 2025; Series 9/10 and Ultra 2 supported) is a biometric-primary smartwatch and the canonical reference of the biometric cohort, with the broadest FDA-cleared portfolio: ECG and AFib/irregular-rhythm notifications (De Novo 2018), sleep-apnea notifications (2024), and hypertension notifications (2025), plus fall and crash detection and the Vitals app. Its sensors (optical PPG, electrical ECG, temperature, accelerometer/gyro, blood-oxygen) need no subscription for the FDA-cleared medical features.

Pricing anchors at about $399 for the Series base (aluminum, GPS), with the Ultra around $799 and the SE around $249 (the SE lacks ECG). A within-entity verified-vs-claimed exemplar: blood-oxygen was disabled in the US in January 2024 over the Masimo ITC ruling and re-enabled in August 2025 via a paired-iPhone calculation redesign. DEPLOY holds the claims to the specific cleared indications: these are cleared features with defined scope, not a general cardiac or sleep diagnostic.

Stelo

Dexcom's Stelo is the first-ever FDA-cleared over-the-counter (no-prescription) glucose biosensor (De Novo, March 5, 2024; US launch August 26, 2024): a 15-day continuous glucose monitor for adults 18+ not on insulin (type 2 not on insulin, plus non-diabetic users tracking how diet and exercise affect glucose). It is the generative-AI end of the glucose cell: Weekly Insights run on Google Cloud's Vertex AI and Gemini, with AI photo meal-logging and personalized daily recommendations, the AI substance that carries it across the biometric boundary.

Pricing is about $89 for a 2-week sensor on a biweekly subscription model (around $99/month). From DexCom (NASDAQ: DXCM), Stelo is the OTC product line, separate from the prescription G7. Cap-flag: the cleared indication is an OTC CGM for adults 18+ not on insulin; it is explicitly NOT cleared for problematic hypoglycemia and has no low-glucose alerts, so it should not be read as a diabetes-management device.

Common questions

How do Apple Watch and Stelo differ?
On DEPLOY's record, Stelo has more verified real-world deployments (2 versus 1) than Apple Watch as of 2026; DEPLOY counts a deployment only when confirmed at a named site with a primary source. Apple Watch has more capabilities independently verified as autonomous (3 vs 0). Stelo has the lower recorded price. Stelo has more verified real-world deployments (2 vs 1).
What is the difference between Apple Watch and Stelo?
Apple Watch and Stelo are both biometric robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.
Which is cheaper, Apple Watch or Stelo?
Stelo has the lower recorded price on the DEPLOY registry than Apple Watch. Prices are sourced; see each record for whether the figure is a manufacturer target, an estimate, or an actual sale price.
Is Apple Watch or Stelo more autonomous?
Apple Watch has more capabilities independently verified as autonomous on the DEPLOY registry than Stelo. DEPLOY counts a capability as autonomous only when verified at a real deployment, not from a demo or a vendor claim.
Which has more verified deployments, Apple Watch or Stelo?
Stelo has more verified deployments (2) on the DEPLOY registry than Apple Watch (1). DEPLOY counts a deployment only when confirmed at a named site with a primary source.

Recent coverage

Related comparisons

Keep researching

Ask the registry

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.


Machine-readable: this page as markdown.

← Back to all consumer robots